Company profile INKT
There is not enough data for MINK Therapeutics -stock to provide analysis
There is not enough data for MINK Therapeutics -stock to provide correlation calculation
There is not enough data for MINK Therapeutics -stock to provide analysis
There is not enough data for MINK Therapeutics AGENT-797 to provide analysis
There is not enough data for MINK Therapeutics AGENT-797 to provide correlation calculation
There is not enough data for MINK Therapeutics AGENT-797 to provide analysis
There is not enough data for MINK Therapeutics clinical trials to provide analysis
There is not enough data for MINK Therapeutics clinical trials to provide correlation calculation
There is not enough data for MINK Therapeutics clinical trials to provide analysis
After 39 days of this quarter the interest is at 55.0. Based on that we can calculate that during remaining 52 days it will total up to 128.0. allogeneic cell therapy expected interest is significantly lower compared to previous quarter (-60.0%) and same quarter last year (-50.2%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 44 | 207 370.5% QoQ | 113 -45.4% QoQ | 175 54.9% QoQ |
| 2020 | 142 222.7% YoY -18.9% QoQ | 183 -11.6% YoY 28.9% QoQ | 146 29.2% YoY -20.2% QoQ | 171 -2.3% YoY 17.1% QoQ |
| 2021 | 108 -23.9% YoY -36.8% QoQ | 0 -100.0% YoY -100.0% QoQ | 201 37.7% YoY inf% QoQ | 217 26.9% YoY 8.0% QoQ |
| 2022 | 296 174.1% YoY 36.4% QoQ | 198 inf% YoY -33.1% QoQ | 260 29.4% YoY 31.3% QoQ | 277 27.6% YoY 6.5% QoQ |
| 2023 | 257 -13.2% YoY -7.2% QoQ | 340 71.7% YoY 32.3% QoQ | 178 -31.5% YoY -47.6% QoQ | 320 15.5% YoY 79.8% QoQ |
| 2024 | 55 -78.6% YoY -82.8% QoQ | - | - | - |
The average 5 years interest of allogeneic cell therapy was 14.9 per week. The last year interest of allogeneic cell therapy compared to the last 5 years has changed by 31.01%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 69.44%.
There is not enough data for invariant natural killer T (iNKT) cell therapy to provide analysis
There is not enough data for invariant natural killer T (iNKT) cell therapy to provide correlation calculation
There is not enough data for invariant natural killer T (iNKT) cell therapy to provide analysis
After 34 days of this quarter the interest is at 422.0. Based on that we can calculate that during remaining 58 days it will total up to 1142.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2018 | - | - | - | 544 |
| 2019 | 956 75.7% QoQ | 951 -0.5% QoQ | 914 -3.9% QoQ | 975 79.2% YoY 6.7% QoQ |
| 2020 | 990 3.6% YoY 1.5% QoQ | 814 -14.4% YoY -17.8% QoQ | 936 2.4% YoY 15.0% QoQ | 929 -4.7% YoY -0.7% QoQ |
| 2021 | 869 -12.2% YoY -6.5% QoQ | 915 12.4% YoY 5.3% QoQ | 951 1.6% YoY 3.9% QoQ | 917 -1.3% YoY -3.6% QoQ |
| 2022 | 886 2.0% YoY -3.4% QoQ | 897 -2.0% YoY 1.2% QoQ | 859 -9.7% YoY -4.2% QoQ | 860 -6.2% YoY 0.1% QoQ |
| 2023 | 947 6.9% YoY 10.1% QoQ | 946 5.5% YoY -0.1% QoQ | 900 4.8% YoY -4.9% QoQ | 422 -50.9% YoY -53.1% QoQ |
The average 5 years interest of cancer treatment was 70.41 per week. The last year interest of cancer treatment compared to the last 5 years has changed by 0.24%. The interest for cancer treatment is relatively stable in the last 5 years. The last year interest is comparable to 5 years ago. It has changed only by -1.58%.
There is not enough data for immune-mediated diseases treatment to provide analysis
There is not enough data for immune-mediated diseases treatment to provide correlation calculation
There is not enough data for immune-mediated diseases treatment to provide analysis
There is not enough data for myeloma treatment to provide analysis
There is not enough data for myeloma treatment to provide correlation calculation
There is not enough data for myeloma treatment to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. solid tumors treatment expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 29 | 211 627.6% QoQ | 223 5.7% QoQ | 124 -44.4% QoQ |
| 2020 | 15 -48.3% YoY -87.9% QoQ | 186 -11.8% YoY 1140.0% QoQ | 59 -73.5% YoY -68.3% QoQ | 96 -22.6% YoY 62.7% QoQ |
| 2021 | 95 533.3% YoY -1.0% QoQ | 89 -52.2% YoY -6.3% QoQ | 172 191.5% YoY 93.3% QoQ | 152 58.3% YoY -11.6% QoQ |
| 2022 | 117 23.2% YoY -23.0% QoQ | 153 71.9% YoY 30.8% QoQ | 99 -42.4% YoY -35.3% QoQ | 188 23.7% YoY 89.9% QoQ |
| 2023 | 70 -40.2% YoY -62.8% QoQ | 113 -26.1% YoY 61.4% QoQ | 86 -13.1% YoY -23.9% QoQ | 182 -3.2% YoY 111.6% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of solid tumors treatment was 9.42 per week. The last year interest of solid tumors treatment compared to the last 5 years has changed by -22.19%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -35.08%.